Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes

What Was Tested

The paper reports a study of Cagrilintide and Semaglutide, published as a randomized controlled trial.

Data are needed on the coadministration of cagrilintide and semaglutide (called CagriSema) for weight management in adults with type 2 diabetes, including those in a subgroup who are undergoing continuous glucose monitoring.

Who Took Part

The age groups tagged for this paper are adults, middle-aged adults and older adults, both men and women.

Additional end points were changes in glycemic measures and safety assessments.

Effect estimates were calculated with the use of the treatment-policy estimand (consistent with the intention-to-treat principle).

How the Study Was Run

The design is described as randomized, double-blind and placebo-controlled.

The participants were allocated by chance, so the Cagrilintide group and the comparison group should start out alike.

As a double-blind Cagrilintide study, the assignments were hidden from both participants and investigators until the end.

A placebo (an inactive look-alike) gave the Cagrilintide group a baseline to be compared against.

What Was Measured

PubMed files the paper under topics including Blood Glucose, Body Mass Index, Diabetes Mellitus, Type 2, Glycated Hemoglobin, Hypoglycemia, Life Style and Obesity.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Cagrilintide and Semaglutide.

The abstract goes on to report its results in about 7 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2025 (The New England journal of medicine), a journal based in United States.

More context: the Cagrilintide compound page and the Semaglutide compound page, all human trials.